Search Result

Results for "

pox+viruses

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CMV (3) DNA/RNA Synthesis (1) Drug Metabolite (1) HSV (2) Influenza Virus (1) Isotope-Labeled Compounds (2) Orthopoxvirus (6) SARS-CoV (1) TNF Receptor (1)
By Research Areas:	Infection (7)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14532

Brincidofovir 5 Publications Verification CMX001; HDP-CDV	CMV HSV Orthopoxvirus	Infection
Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo .

HY-124564

Methisazone Marboran	SARS-CoV Orthopoxvirus	Infection
Methisazone (Marboran) is an antiviral agent that works by inhibiting mRNA and protein synthesis. Methisazone is also a SARS-CoV-2 (COVID-19) inhibitor. Methisazone is mainly used in pox viruses .

HY-14532S

Brincidofovir-d6 CMX001-d₆; HDP-CDV-d₆	Isotope-Labeled Compounds HSV CMV Orthopoxvirus	Infection
Brincidofovir-d₆ (CMX001-d₆) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. .

HY-162517

UMM-766	Orthopoxvirus	Infection
UMM-766 is an orally available nucleoside analog. UMM-766 has potent, broad-spectrum antiviral activity against multiple members of the pox virus family. UMM-766 provides protection in a murine model of orthopox disease .

HY-131606S

Cidofovir diphosphate-13C3	Isotope-Labeled Compounds Orthopoxvirus Drug Metabolite CMV DNA/RNA Synthesis	Infection
Cidofovir diphosphate- ¹³C₃ is the ¹³C-labeled Cidofovir diphosphate (HY-131606). Cidofovir diphosphate is the intracellular active metabolite of Cidofovir (HY-17438) and its oral prodrug Brincidofovir (HY-14532). By inhibiting viral DNA polymerase (Ki ≈ 76.3 μM), cidofovir diphosphate is widely used in studies on double-stranded DNA virus infections, including cytomegalovirus (CMV), adenovirus (AdV), and poxviruses (such as monkeypox and molluscum contagiosum virus, MCV) .

HY-173595

ODE-(S)-HPMPA formate	Influenza Virus TNF Receptor	Infection
ODE-(S)-HPMPA formate is an antiviral compound with strong inhibitory activity against poxviruses and adenoviruses. ODE-(S)-HPMPA formate activates TNF-α secretion .

HY-180785

G243-1720	Orthopoxvirus	Infection
G243-1720 is a potent, orally active, broad-spectrum anti-orthopoxvirus agent that functions by targeting the OPG57 (F13) protein and inducing its dimerization. G243-1720 effectively inhibits the replication of various poxviruses, but has no inhibitory effect on non-poxviruses. G243-1720 prevents the formation of extracellular membrane virus particles and the spread between cells. G243-1720 significantly reduces the viral load of monkeypox virus (MPXV) in the lungs of mice

Cat. No.	Product Name	Chemical Structure

HY-14532S

Brincidofovir-d6
Brincidofovir-d₆ (CMX001-d₆) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. .

Brincidofovir-d6

Brincidofovir-d₆ (CMX001-d₆) is the deuterium labeled Brincidofovir (HY-14532). Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo. .

HY-131606S

Cidofovir diphosphate-13C3
Cidofovir diphosphate- ¹³C₃ is the ¹³C-labeled Cidofovir diphosphate (HY-131606). Cidofovir diphosphate is the intracellular active metabolite of Cidofovir (HY-17438) and its oral prodrug Brincidofovir (HY-14532). By inhibiting viral DNA polymerase (Ki ≈ 76.3 μM), cidofovir diphosphate is widely used in studies on double-stranded DNA virus infections, including cytomegalovirus (CMV), adenovirus (AdV), and poxviruses (such as monkeypox and molluscum contagiosum virus, MCV) .

Cidofovir diphosphate-13C3

Cidofovir diphosphate- ¹³C₃ is the ¹³C-labeled Cidofovir diphosphate (HY-131606). Cidofovir diphosphate is the intracellular active metabolite of Cidofovir (HY-17438) and its oral prodrug Brincidofovir (HY-14532). By inhibiting viral DNA polymerase (Ki ≈ 76.3 μM), cidofovir diphosphate is widely used in studies on double-stranded DNA virus infections, including cytomegalovirus (CMV), adenovirus (AdV), and poxviruses (such as monkeypox and molluscum contagiosum virus, MCV) .

Cat. No.	Product Name		Classification

HY-14532

Brincidofovir 5 Publications Verification CMX001; HDP-CDV		Phospholipids
Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.